Aciclovir‐resistant herpes keratitis

Choong, Keat; Walker, Nathan J.; Apel, Andrew; Whitby, Michael

doi:10.1111/j.1442-9071.2010.02209.x

Cited by 35 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The triphosphate forms of these analogues selectively inhibit the viral DNA polymerase (DNA pol) activity. After more than three decades of ACV administration, drug-resistant HSV isolates are rarely found in immunocompetent subjects (0.1–0.7%) but more frequently recovered from immunocompromised patients (4–14%) [12, 34, 36, 47]. HSV resistance to ACV generally arises as a result of mutations in viral thymidine kinase and in a lesser number from mutations in the viral DNA pool [19, 38].…”

Section: Introductionmentioning

confidence: 99%

Safety, Formulation and In Vitro Antiviral Activity of the Antimicrobial Peptide Subtilosin Against Herpes Simplex Virus Type 1

Torres

Noll

et al. 2013

Probiotics & Antimicro. Prot.

108

View full text Add to dashboard Cite

In the present study the antiviral properties of the bacteriocin subtilosin against Herpes simplex virus type 1 (HSV-1) and the safety and efficacy of a subtilosin-based nanofiber formulation were determined. High concentrations of subtilosin, the cyclical antimicrobial peptide produced by Bacillus amyloliquefaciens, were virucidal against HSV-1. Interestingly, at non-virucidal concentrations, subtilosin inhibited wild type HSV-1 and aciclovir-resistant mutants in a dose-dependent manner. Although the exact antiviral mechanism is not fully understood, time of addition experiments and western blot analysis suggest that subtilosin does not affect viral multiplication steps prior to protein synthesis. Poly(vinyl alcohol) (PVOH)-based subtilosin nanofibers with a width of 278 nm were produced by the electrospinning process. The retained antimicrobial activity of the subtilosin-based fibers was determined via an agar well diffusion assay. The loading capacity of the fibers was 2.4 mg subtilosin/g fiber, and loading efficiency was 31.6%. Furthermore, the nanofibers with and without incorporated subtilosin were shown to be nontoxic to human epidermal tissues using an in vitro human tissue model. Taking together these results subtilosin-based nanofibers should be further studied as a novel alternative method for treatment and/or control of HSV-1 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety, Formulation and In Vitro Antiviral Activity of the Antimicrobial Peptide Subtilosin Against Herpes Simplex Virus Type 1

Torres

Noll

et al. 2013

Probiotics & Antimicro. Prot.

108

View full text Add to dashboard Cite

show abstract

“…Virological resistance is one of the reasons for therapeutic unresponsiveness in suspected herpetic keratitis, a dilemma that may lead to the selection of an alternative antiviral (Hlinomazová 2010). If resistant ocular HSV strains continue to emerge (Choong 2010; Hlinomazová 2010) the applicability of this review may need to be modified.…”

Section: Discussionmentioning

confidence: 99%

Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis

Wilhelmus

2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…A study showed that a single amino acids change in primase protein with no change in the UL5 helicase leads to moderate resistance while single change in UL5 helicase results in co-resistance to both agents. [39] A source of worry is cross resistance in antiviral therapy; [40] a study by Moira et al, showed that acyclovir resistant to HSV also confers resistant to the same agent in HSV/HIV co-infection. The resistant associated with HIV was due to mutation in the reverse transcriptase [41] while another studies established cross resistance in ACV-resistant strain and brivudin and penciclovir as well as foscarnet.…”

Section: Mechanism Of Antiviral Drug Resistancementioning

confidence: 98%

Epstein-Barr infection: Current treatment options

Yaro¹

2013

Ann Trop Med Public Health

View full text Add to dashboard Cite

Epstein-Barr virus is one of the causes of known human cancers such as PLTD, BL and XLP. It is persistent in about 90% of the global population. Prevalent antiviral agents are not effective. A systematic review was undertaken to discuss current treatment options available for EBV infection. A search was made of PubMed to identify relevant papers published from 2000 to 2010 using various search indexes. The review is based on 11 articles included in the study. The result showed that there is no studies which analyzed antiviral agents in EBV infection. Combinational therapy using antiviral agents, immunotherapy and anticancer agents should be considered while antibiotic regimen should be considered to take care of any sepsis. Resistance to antiviral agents especially cross-resistance is burden in EBV infection Studies should be undertaken to evaluate resistance pattern in EBV infection. To assess the efficacy of EBV therapeutics. Viral load using molecular techniques should be used as biomarker of efficacy.

show abstract

Aciclovir‐resistant herpes keratitis

Cited by 35 publications

References 28 publications

Safety, Formulation and In Vitro Antiviral Activity of the Antimicrobial Peptide Subtilosin Against Herpes Simplex Virus Type 1

Safety, Formulation and In Vitro Antiviral Activity of the Antimicrobial Peptide Subtilosin Against Herpes Simplex Virus Type 1

Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis

Epstein-Barr infection: Current treatment options

Contact Info

Product

Resources

About